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Genetic defects and inhibitor development in siblings
with severe hemophilia A
The formation of inhibitory allo-anti-bodies against the deficient factor is aserious complication of replacement
therapy in patients with hemophilia.1,2 In
the case of hemophilia A, the antibodies
inhibit the function of factor VIII and devel-
op in approximately 30% of all subjects suf-
fering from the severe form of the disease.
In many cases these inhibitors become a
long-standing problem that seriously affects
health and quality of life and requires cost-
ly medical intervention.3 Several genetic and
environmental risk factors for the develop-
ment of inhibitors have been evaluated, but
in most cases without significant associa-
tions being found.4-5 The strongest relation-
ship that has been found is with the
causative factor VIII gene mutation.6-7
Patients with large gene deletions, nonsense
mutations and intrachromosomal aberra-
tions appear to have a relatively high risk of
inhibitor development, whereas those with
missense mutations, small deletions/inser-
tions and splice site mutations experience
this side-effect less frequently. A weak cor-
relation has also been found with the major
histocompatibility complex (MHC) class
I/II genotypes, in that A3, B7, C7,
DQA0102, DQB0602 and DR15 have been
associated with relative risks from 1.9-4.0
for inhibitor development.8,9 However, sev-
eral patients with high-risk mutations and
unfavorable genotypes do not develop
inhibitors and the reason for this is
unknown. The aim of the Malmö
International Brother Study (MIBS) is to
identify risk factors for inhibitor develop-
ment. The study cohort consists of families
containing two or more siblings with
hemophilia with or without a history of
inhibitors. In an analysis of 249 families
with severe hemophilia A, we found an
overall concordance between siblings of
78.3% and a relative risk of 3.2 for the
development of an inhibitor for a patient
whose older brother had previously been
diagnosed with an inhibitor.10 The study of
factors affecting the immune response to
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Background and Objectives. The strongest risk factor identified for inhibitor develop-
ment in people with severe hemophilia A is the type of factor VIII gene mutation. The
objective of this study was to evaluate the mutation type dependent concordance rate
of inhibitor formation in siblings. 
Design and Methods. The gene defect, treatment and inhibitor history were evaluated
in 113 families in which two or more siblings had severe hemophilia A. 
Results. Seventy-nine of the families (69.9%) were concordant in that either all or none
of the siblings had a history of inhibitors. The concordance in 59 families with
inhibitors was 42.4%. The corresponding figures for the 74 families with intron 22
inversion were 63.5% and 40.0%, respectively, and the overall concordance within 14
families with nonsense mutations was 78.6%. The siblings in two families with large
gene deletions had no inhibitor history. A small proportion of the families with mis-
sense mutations, small deletions/insertions and splice site mutations developed
inhibitors, but in four of the families two or more siblings developed high-responding
inhibitors. In 18 of the 25 concordant families (72.0%) with inhibitors, the inhibitor was
also of the same type (high-responding). 
Interpretations and Conclusions. This is the first study of the association between
inhibitor formation and the causative factor VIII gene mutation in siblings. The data
show that the type of mutation provides, to some extent, the basis for this relation-
ship, but the mutation itself is not enough to predict the risk for therapy-induced
inhibitor formation.
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replacement therapy in siblings offers many benefits.
The factor VIII gene mutation and the amount of circu-
lating endogenous factor VIII antigen will be similar in
all affected family members, and the variation and
impact of socio-economic and environmental factors
can be minimized. Previous family studies have not
addressed the relationship between inhibitor develop-
ment and the type of factor VIII mutation.10,11 Since the
type of mutation will be important when interpreting
concordance within families, we evaluated the factor
VIII gene defect and inhibitor history in 113 MIBS fam-
ilies with severe hemophilia A. We also compared our
findings with the incidence figures and data available
from the two largest registries of unrelated patients
with hemophilia i.e. the one at the Bonn center and the
database of the Haemophilia A Mutation, Structure,
Test and Resource Site (HAMSTeRS).12,13
Design and Methods
Subjects
Centers participating in the Malmö International
Brother Study (MIBS) were given a standardized
questionnaire to accrue data from twins and non-
twin brothers with severe hemophilia A (factor
VIII:C <1%). Date of birth, ethnicity, type of hemo-
philia, treatment history, inhibitor history including
peak titer and current titer in Bethesda units
(BU/mL), type of causative factor VIII gene mutation
and techniques used for analysis were recorded. In
the case of twins, data concerning zygosity were
requested. All families in which the factor VIII gene
mutation was fully characterized were enrolled in
the study. A high-responding inhibitor was defined
as a historical peak titer >5 BU/mL and a low-
responding inhibitor as one with a peak titer of ≤5
BU/mL.14 The study was approved by the independ-
ent review board (IRB) and ethics committee.
Methods
Standard methods for genetic analyses were used
including Southern blot and long range polymerase
chain reaction (PCR) for inversion analysis, PCR and
mutation screening methods, e.g. chemical mismatch
cleavage (CMC), single stranded conformation poly-
morphism (SSCP), denaturing gradient gel elec-
trophoresis (DGGE), denaturing high performance
liquid chromatography (DHPLC), and direct DNA
sequencing.15 Splice site scores were calculated
according to the website available at URL http://cgsig-
ma.cshl.org/new_alt_exon_db2/HTML/score.html.
Inhibitory antibodies were quantified according to
the original Bethesda method and the Nijmegen
modified assay.16,17
Statistical methods
The number of expected concordant families with
intron 22 inversion and inhibitors in both siblings
was calculated using the formula (i): [Expected
inhibitor incidence in % i.e. either 21.0% (based on
the Bonn data for unrelated patients) or 34.4% (based
on the HAMSTeRS data for unrelated patients)/
100]sibling 1 ¥ [Inhibitor incidence in %/100] sibling 2 ¥74
(i.e. the total number of families with this type of
mutation). The expected number of concordant fam-
ilies without inhibitors in both siblings was calculat-
ed using the formula (ii): [100 – Expected inhibitor
incidence in % / 100] sibling 1 ¥ [100 - Inhibitor incidence
in % / 100] sibling 2 ¥ 74. The number of discordant fam-
ilies was calculated using the formula (iii): [Expected
inhibitor incidence in % / 100] sibling 1 ¥ [100 - Inhibitor
incidence in % / 100] sibling 2 ¥ 2 ¥ 74. c2 analysis was
used for evaluation of the observed versus expected
number of concordant and discordant families. A p




The types of FVIII gene mutations identified in the
113 families containing 231 members with severe
hemophilia A were intron 22 inversion in 74 families
(150 subjects), nonsense mutations in 14 families (28
subjects), large gene deletions in 4 families (8 sub-
jects), missense mutations in  9 families (20 subjects),
small deletions/insertions in 9 families (19 subjects)
and splice site mutations in 3 families (6 subjects).
The median age was 31 years and all family mem-
bers were above the age of 4 years. Two monozygot-
ic twins were included. All families were of
Caucasian ethnicity, except for 7 African-American
families, and all subjects had been extensively
exposed to factor VIII concentrates, far above the
number of exposure days normally regarded as the
highest risk period for inhibitor development i.e.
<50-75 days. The inhibitor characteristics for each
subgroup of mutation are shown in Table 1. The sib-
lings in 79 of the 113 families (69.9%) were concor-
dant in that either all siblings developed inhibitors or
none of them did. The siblings in the remaining 34
families were discordant. All siblings had a history of
inhibitor development in 25 out of the 59 inhibitor
families (42.4%) and in 18 of these families (72.0%)
the inhibitor was of the same type (high-responding).
Altogether 88 of the 231 patients in the cohort
(38.1%) had a history of inhibitors and in 70 of these
cases (79.6%), the inhibitor was of the high-respond-
ing type. 
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Intron 22 inversion
Inhibitors were described in 45 of the 74 families
with intron 22 inversion (60.8%) and in 65 of the
total 150 patients with this mutation (43.3%). This is
higher than the incidence of inhibitors for this muta-
tion reported in unrelated patients from Bonn
(21.0%) or in the HAMSTeRS database (34.4%).
According to the figures in the databases, the expect-
ed number of concordant siblings with an inhibitor
history in the 74 families in our series would have
been 3.3 and 8.8 depending on which figure is used
(Bonn vs. HAMSTeRS). However, the number of
families with more than one sibling having a history
of inhibitor in the study was 19, including an
inhibitor discordant family with three siblings, two
of whom had an inhibitor and one who did not. The
corresponding expected numbers of discordant fami-
lies with an inhibitor in only one of the siblings are
24.6 and 33.4, and the observed number of families
was 26. The number of observed concordant families
without an inhibitor history was 29 compared with
the expected 31.8 and 46.2. The overall number of
completely concordant families within the intron 22
inversion subgroup was 63.5% (47 out of 74 fami-
lies). Among the 45 families with inhibitors, 18
(40.0%) were concordant in that all siblings had
developed an inhibitor. The peak titers in these 18
concordant families ranged from 2.2 to >1,000
BU/mL (median titer 100 BU/mL). In the families
with one sibling having a high- and one having a
low-responding inhibitor, the peak titers for the high-
responding patients were between 6.6 and >1,000
BU/mL. In the 26 discordant families, with an
inhibitor identified in only one of the siblings, the
peak titers varied from 1.0 to >1,000 BU/mL (median
titer 17 BU/mL). The number of families with con-
cordant siblings was significantly higher than the
expected number in unrelated subjects (p<0.001). 
Non-intron 22 inversion mutations
The non-intron 22 inversion mutations associated
with inhibitors in our series are described in Table 2
together with the inhibitor response and peak titer in
each sibling. The mutations without associated
inhibitors are summarized in Table 3.
Nonsense mutations
As shown in Table 1, six of the 14 families and nine
of all 28 siblings with nonsense mutations had devel-
oped inhibitors. This proportion of inhibitors is con-
sistent with an inhibitor incidence of 31.0-38.4%
observed in the databases for this subgroup of factor
VIII mutations. The locations of the four mutations
found in the six inhibitor families are shown in Table
2. Most of these mutations are located in the C1/C2
domains and have been relatively frequently report-
ed to the databases.6,18-22 The only mutation not previ-
ously associated with inhibitors is the S2058X muta-
tion in exon 21 found in a discordant brother-pair
with a high-titer inhibitor. Among the seven non-
sense mutations in our series without inhibitors, four
were novel and three had been previously
described23,24 (Table 3). The overall concordance with-
in the subgroup of nonsense mutations was 78.6%. 
Large deletions
The number of families with large deletions was
small and no major conclusions can be made.
However, according to database reports, the occur-
rence of inhibitor development associated with this
type of mutation is high (35.7-41.0%) and it is inter-
esting to note that a brother-pair with an exon 7 dele-
tion was discordant and none of the siblings with the
exon 26 and exon 1-6 deletions has developed
inhibitory antibodies (Tables 1 and 2). The only con-
cordant family with high-responding inhibitors in
both siblings was that with a deletion of exons 11 to
25. This mutation, as well as the exon 1-6 deletion,
has previously been associated with inhibitors,
whereas no consistent associations with inhibitors
have been reported for the other two mutations.25,26
Missense mutations
Inhibitors were described in three of nine families
and four out of 20 siblings with missense mutations
(Tables 1 and 2). According to the databases, the inci-
dence of inhibitors in this subgroup is low (4.3-5.0%).
However, in the family with the G686R mutation,
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Table 1. Number of concordant and discordant families divided
into subgroups according to factor VIII gene mutation. The fami-
lies with more than two siblings are included in the total number
of families, but described in the footnote. Low- and high-respond-
ing inhibitors are defined as a historical peak titer £  5 and >5
BU/mL, respectively (No: no history of inhibitors).
Type of Total no. Inhibitor history in sibling1/sibling2
mutation of families
High/ High/ High/ Low/ No/
High Low No No No
Intron 22 inv 74* 12 5 17 9 29
Nonsense mutation 14 2 1 3 8#
Missense mutation 9° 2 6
Large deletion 4 1 1 2
Small deletion/ 9§ 2 6
insertion
Splice site mutation 3 3
Total 113 17 6 21 11 54
*Including 1 family with 3 siblings; two with high-responding inhibitors and one
without a history of inhibitor and 1 family with 3 siblings of whom two were
monozygotic twins and all had high-responding inhibitors; #including one pair
of monozygotic twins; °including family with 4 siblings; two with high-responding
inhibitors and two without inhibitors; §including 1 family with 3 siblings; two with
high- and one with low-responding inhibitors.
Factor VIII mutation and inhibitors in siblings
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two of the four brothers developed high-responding
inhibitors (Table 2). This mutation is located in the
A2-domain and has not been reported to the
HAMSTeRS database. The mutation affects the donor
splice site of exon 13, since the first nucleotide of the
glycine codon GGT is the last nucleotide of exon 13.
The donor splice score is reduced from 8.1 to 4.2, thus
almost abolishing the splice site and causing a severe
hemophilia A phenotype, similar to that caused by a
serine substitution at the same location reported in the
HAMSTeRS database. The S534P and N684D muta-
tions have previously been identified, but not associ-
ated with inhibitors.20,23 Among the remaining mis-
sense mutations found in the MIBS families without
inhibitors, two mutations were novel, and only
R2304C has previously been associated with
inhibitors27-29 (Table 3). 
Small deletions/insertions 
Inhibitors were found in three out of nine families
and seven out of 19 subjects with small deletions or
insertions (<50 bp). Interestingly, all three families
were concordant in that all siblings developed
inhibitors (Table 2). The nt118C deletion and the
deletion in codons 1012-1013 (nt3091-3094AAGA
del) cause a frameshift and were associated with
high-responding inhibitors. The nt4838Adel muta-
tion generates a subsequent stop codon and is not
Table 2. Mutation type and peak titers found in the siblings of 14 non-intron 22 inversion families with a history of inhibitors. Low- and
high-responding inhibitors are defined as described in Table 1.
Type of mutation Type of family Mutation/ Type of inhibitor Peak titer Novel Associated
Amino acid change response (BU/mL) mutation with inhibitors
in each sibling (Yes/No) in the databases
(Yes/No)
Nonsense Concordant R1966X High/High 934 (B1) 34 (B2) No Yes
Discordant S2058X No/High 150 (B2) No No
Discordant R2147X No/High 81 (B2) No Yes
Concordant R2209X High/High >1,000 (B1) 18 (B2) No Yes
Concordant R2209X High/Low 563 (B1) 0.8 (B2) No Yes
Discordant R2209X High/No 909 (B1) No Yes
Large deletion Discordant Exon 7 del High/No 110 (B1) No Not known*
Concordant Exon 11-25 del High/High >1,000 (B1) >1,000 (B2) No Yes
Missense Discordant S534P No/Low 4 (B2) No No
Discordant N684D Low/No 1 (B1) No No
Discordant G686R No/No/High/High 55 (B3) 12 (B4) Yes -
Small deletion Concordant nt 118 C del High/High 8 (B1) 15 (B2) No Yes
Concordant nt 3091-3094 AAGA del High/High 20 (B1) 566 (B2) No Yes
Concordant nt 4838 A del High/High/Low 7 (B1) 5.6 (B2) 3 (B3) Yes -
Discordant: inhibitors in only one or two of the siblings; concordant: inhibitors in all siblings; no: no history of inhibitors; B1: the oldest brother in the family;
B2-4: the younger siblings in consecutive order to B1; *not known: missing data in the databases.
Table 3. Mutation type found in the 25 non-intron 22 inversion
families without any family history of inhibitors. 
Type of Mutation/ No. of Novel Associated with
mutation Amino acid families mutation inhibitors
change (siblings) (Yes/No) in the databases 
(Yes/No)
Nonsense W1535X 1 (2) Yes -
Y1748X 1 (2) Yes -
W2062X 1 (2) Yes -
L2178X 1 (2) Yes -
R336X 1 (2) No Yes
R795X 2 (4) No No
Q1686X 1 (2) No No
Large deletion Exon 1-6 del 1 (2) No Yes
Exon 26 del 1 (2) No Yes
Missense S1849L 1 (2) Yes -
C2169Y 1 (2) Yes -
T118I 1 (2) No No
N1922S 1 (2) No No
R2304C 2 (4) No Yes
Small deletion/ nt2057-2060CACTdel 2 (4) Yes -
insertion nt2062Ains 2 (4) No No
nt4321-4324AGAAdel 1 (2) No No
nt4820-4825Ains 1 (2) No Yes
Splice site IVS4 + 5GÆA 1 (2) Yes -
IVS6 + 3AÆG 1 (2) No No
IVS11 + 1GÆA 1 (2) Yes -
J. Astermark et al.
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found in the HAMSTeRS database. The families
without inhibitors had a deletion or insertion in exon
13 involving codons 667-669 or in exon 14 (Table 3).
Insertion at codon 669 has also been reported to the
database without any associated inhibitor. The
HAMSTeRS and Bonn data suggest an average
inhibitor incidence of 7.4-16.0% for patients with
small deletions/insertions, but the figures vary
depending on the location of the mutation. 
Splice site mutations
Splice site mutations have been associated with an
inhibitor incidence of approximately 3% and, consis-
tent with this low-risk profile, no inhibitor history
was reported in the small group of three families
with this type of mutation in our series (Table 3).
Discussion
Both genetic and environmental factors must be
considered as determinants in the formation of
inhibitory antibodies. One attractive way to address
the issue of etiology is to study related subjects, since
patients within a family will carry the same causative
gene mutation, a similar amount of circulating anti-
gen and are more homologous with respect to other
immunological genes than unrelated subjects. In
addition, the impact of environmental and epigenet-
ic factors will be minimized. Therefore, family stud-
ies of the rate of inhibitor concordance should lead to
more accurate findings than studies of unrelated sub-
jects. The present study is the first to evaluate how
different factor VIII gene mutations relate to therapy-
induced inhibitor formation in siblings. Except for
families with the intron 22 inversion, the number of
families in each subgroup was low. However, the
study was not designed to evaluate the risk of
inhibitors in each subgroup of mutation, but focuses
on the concordance rate between siblings having the
same genetic basis for the disease in order to extend
the knowledge about the influence of genetic and
environmental factors. A large proportion of the fam-
ilies had the intron 22 inversion (65.5%). This may
be explained by the fact that this mutation is easily
tested for in most laboratories, whereas the identifi-
cation of other mutations requires more effort and is
not always performed. Although the questionnaire
asked for siblings with a phenotype of severe hemo-
philia A and a FVIII:C level <1%, three of the mis-
sense mutations, i.e. T118I, N1922S and R2304C,
have also been associated with a more moderate
phenotype in the HAMSTeRS database.27-29 This
reflects the variation in classification that can be seen
in international multicenter studies and the reason
why a definition of <2% for severe hemophilia is
used in most studies. However, in our study, the
FVIII:C level is less crucial, since the concordance rate
in the families is related to the causative mutation. In
agreement with previous data, we found that the
type of factor VIII gene mutation appears to play an
important role in that large rearrangements of the
gene and other protein-truncating mutations were
relatively frequently associated with inhibitors.
However, even though the concordance within fam-
ilies was high, it is obvious that the mutation itself
does not supply sufficient information to predict
whether therapy-induced inhibitory antibodies will
develop or not. The overall figure of 69.9% concor-
dance includes both inhibitor-negative and inhibitor-
positive families and suggests that other unidentified
genetic factors are as important as the factor VIII
gene mutation itself. This is even more obvious
when analyzing concordance in the subgroup of fam-
ilies with an inhibitor history in at least one of the
siblings. In this subgroup, the figure was approxi-
mately 40% both overall and in the largest subgroup
of patients with intron 22 inversion. Interestingly,
although perhaps only of anecdotal value, the
monozygotic twins with intron 22 inversion and
those with nonsense mutation were both concor-
dant. The mutations belong to the high-risk group,
but only the twins with the inversion had developed
inhibitors. The type of inhibitor response was the
same in 18 of the 25 concordant families with
inhibitors in all siblings. The factors that determine
the type of inhibitor are not known, but it is tempt-
ing to believe that mutations and polymorphisms in
genes for co-factors and cytokines involved in the B-
and T-cell interaction may either stimulate or sup-
press the native immune response. It is well known
that both hemophiliacs and normal subjects form
antibodies to factor VIII,30-32 but it has not yet been
established whether the immune response associated
with the formation of non-inhibitory antibodies in
patients with hemophilia is different from that caus-
ing inhibitory antibodies. It would be important to
evaluate the presence of non-inhibitory as well as
anti-idiotypic antibodies in the discordant siblings,
since this may add additional information about how
siblings within the same family react against replace-
ment therapy.
Some of the observed mutations require additional
comments. The nonsense mutation R2209X was
found in three unrelated families, two of which were
concordant for inhibitors and one discordant with a
high-responding inhibitor in only one of the siblings.
This mutation, which is located in the C2 domain, has
previously been associated with inhibitors and
patients with this mutation seem to be at high risk of
Factor VIII mutation and inhibitors in siblings
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forming inhibitory antibodies. The reason why one of
these siblings did not develop inhibitors is unknown. 
The missense mutation G686R in the A2-domain
has not previously been described, but was found in
a family with four siblings. The mutation affects the
donor splice site of exon 13 to an extent similar to
that observed with the serine substitution at the
same location and reported to the HAMSTeRS data-
base. Both mutations are associated with a severe
phenotype. Two of the siblings with the G686R
mutation had developed inhibitors while two had
not. They are all between 6 and 9 years of age. The
two siblings without inhibitors have been on pri-
mary prophylaxis for several years and have had well
above the critical level of exposure to replacement
therapy. While the mechanism of inhibitor formation
can be explained for the G686R mutation, it is
unknown for the other two missense mutations,
S534P and N684D. Both positions are completely
conserved in the gene sequence for human, porcine,
murine and canine factor VIII in the HAMSTeRS
database, indicating a crucial role for protein func-
tion. Moreover, in the S534P variant, proline repre-
sents a helix-breaking amino acid likely to change the
three dimensional structure of the factor VIII protein,
while N684D represents a non-conservative amino
acid exchange with respect to acidity and polarity. In
the HAMSTeRS mutation database the S534P variant
has been reported in two patients without inhibitor
formation. 
The small deletions of a nucleotide in exon 1
(C118) and four nucleotides in exon 14 (AAGA 3091-
3094) were found in families in which both brothers
had developed high-responding inhibitors. The
mutations create a frameshift and have, according to
the HAMSTeRS database, been associated with
inhibitors in other cases. 
A weakness of all retrospective analyses of
inhibitors is that some transient and low-responding
inhibitors may be overlooked. In addition, no data
are available to characterize the presence of non-
inhibitory antibodies. In our cohort of families with
predominantly clinically significant, high-responding
inhibitors (79.6% of all inhibitors in our series), the
data indicate a genetic predisposition to inhibitor
development. The fundamental capacity of patients
to develop therapy-induced inhibitory antibodies
probably relates to the type of causative gene defect,
but several other mutations and/or polymorphisms
will affect the final outcome. In addition, even in
family studies, non-genetic factors may differ and the
impact of these parameters remains to be settled. To
fully appreciate the nature of all significant genetic
factors involved,  including the role of the MHC class
I/II system and different cytokines, genome screen-
ing of large cohorts of patients and their relatives is
warranted.
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